



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** Anti-HIV-1 gp120 Monoclonal (F105)

**Catalog Number:** 857

**Lot Number:** 060798

**Release Category:** C

**Provided:** 100 µg at 1.5 mg/ml. Protein G-purified from tissue culture supernatant, quantitated by ELISA and dialyzed against PBS. The antibody is stable at this concentration. If a less concentrated stock is needed, dilute the material no further than 1 mg/ml, and use it within three months.

**Host Site:** Human EBV-transformed B cell x HMM2.11TG/O myeloma.

**Titer:** Use 2 µg of antibody per million cells in flow cytometry and immunofluorescence assays, and 1-10 µg/ml for neutralization assays. Other applications will vary with the requirements of the experimental system.

**Special Characteristics:** F105 reacts with a discontinuous, or conformational, gp120 epitope. Binds to gp120 on the surface of IIIB, SF2, MN, RF, and CC-infected cells. Neutralizes SF2, IIIB, and MN infection at concentrations ranging from 140 ng/ml to 10 µg/ml.

Endotoxin: 24.319 EU/mL\*

\*NOTE: Endotoxin has been shown to induce chemokines and other soluble HIV and SIV inhibitory factors in primary cultures of PBMC, monocytes and macrophages (Verani et al., J Exp Med 185:805-816, 1997; J Immunol 168:6388-6396, 2002; Montefiori in preparation). Thus, caution is advised when using this reagent for in vitro studies involving primary cells.

**Recommended Storage:** Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

**Contributor:** Dr. Marshall Posner and Dr. Lisa Cavacini.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Isotype:** IgG<sub>1</sub>, kappa.

**References:** Posner MR, et al. *J Acquired Immune Defic Syndr* **6**:7-14, 1993. Cavacini LA, et al. *J Acquired Immune Defic Syndr* **6**:353-358, 1993. Posner MR, et al. *Hybridoma* **6**:611-625, 1987. Posner MR, et al. *J Immunol* **146**:4325-4332, 1991.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (F105) from Dr. Marshall Posner and Dr. Lisa Cavacini." Also include the references cited above in any publications.

**US Patent No. 5215913. Requests from commercial organizations should be directed to Jodi Hecht, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Email: [jehecht@bidmc.harvard.edu](mailto:jehecht@bidmc.harvard.edu).**

**Last Updated** May 18, 2015

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.